Uridine phosphorylase-1 supports metastasis by altering immune and extracellular matrix landscapes
Declan Whyte, S Fisher, Christopher G J McKenzie, David Sumpton, Sandeep Dhayade, Emmanuel Dornier, M. H. Moore, David Novo, Jasmine Peters, Robert Wiesheu, Michalis Gounis, Dale M. Watt, John B. G. Mackey, Amanda J. McFarlane, Frédéric Fercoq, C. Caballero, Keara L. Redmond, Louise Mitchell, E. S. Anderson, Gemma Thomson, A J Hedley, William Clark, Shannen Leroi, Lindsey N. Dzierozynski, Juan J Apiz Saab, Caroline A. Lewis, Alexander Muir, Christopher J. Halbrook, Douglas Strathdee, René Jackstadt, Colin Nixon, Philip D. Dunne, Leo M. Carlin, Iain R. Macpherson, Edward W. Roberts, Seth B. Coffelt, Karen Blyth, Owen J. Sansom, Jim C. Norman, Johan Vande Voorde, Cassie J. Clarke
Abstract
Understanding mechanisms that facilitate early events in metastatic seeding is key to developing therapeutic approaches to reduce metastasis. Here we identify uracil as a metastasis-associated metabolite in genetically engineered mouse models of cancer and in patients with metastatic breast cancer. Uracil is generated by the enzyme uridine phosphorylase-1 (UPP1), and we find that neutrophils are a significant source of UPP1 in metastatic cancer. Mammary tumours increase expression of adhesion molecules on the neutrophil surface, in a UPP1-dependent manner, leading to decreased neutrophil motility in the pre-metastatic lung. UPP1-expressing neutrophils suppress T-cell proliferation, and the UPP1 product uracil increases fibronectin deposition in the extracellular microenvironment. Knockout or inhibition of UPP1 in mice with mammary tumours increases T-cell numbers and reduces fibronectin content in the lung, and decreases the proportion of mice that develop lung metastasis. These data indicate that UPP1 influences neutrophil behaviour and extracellular matrix deposition in the lung, and suggest that circulating uracil could be a marker of metastasis, and that pharmacological inhibition of UPP1 could be a strategy to reduce recurrence.